Exicure, Inc. - News

2021 2020 2019 2018 2017 2016 2015 2014

12/23/2019

Exicure Announces the Closing of its Offering of Common Stock

12/19/2019

Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock

12/18/2019

Exicure Announces Proposed Public Offering of Common Stock

12/16/2019

Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board

12/11/2019

Exicure Reports Activity of AST-008 in Patients with Merkel Cell Carcinoma and Will Enroll Patients in Phase 2 Study

11/14/2019

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

11/13/2019

Exicure’s CEO David Giljohann Honored in Crain’s 40 Under 40 Class of 2019

11/07/2019

Exicure Reports Third Quarter 2019 Financial Results and Recent Developments

10/21/2019

Exicure to Present at 2019 BIO Investor Forum

10/16/2019

Exicure Presents Positive Biomarker Results from Clinical Trial of XCUR17

10/14/2019

Exicure to Present Clinical Results from XCUR17 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society

09/17/2019

Exicure to Present at 2019 International Oligonucleotide and Peptide Conference

09/03/2019

Exicure to Present at Upcoming Investor Conferences

08/08/2019

Exicure Reports Second Quarter 2019 Financial Results and Recent Developments

08/07/2019

Exicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors

08/02/2019

Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

07/31/2019

Exicure Announces Uplisting to Nasdaq Capital Market and Pricing of $55 Million Public Offering of Common Stock

07/30/2019

Exicure Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

07/22/2019

Exicure Appoints Jeffrey L. Cleland and Tim Walbert to Board of Directors

07/11/2019

Exicure Co-Founder Chad Mirkin Wins Kabiller Prize in Nanoscience and Nanomedicine

06/26/2019

Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System

06/03/2019

Exicure to Present at LD Micro 9th Invitational Conference

05/22/2019

Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008

05/09/2019

Exicure to Present Poster at SID 2019 Annual Meeting Demonstrating Bi-Specific Gene Targeting in Dermatology

05/08/2019

Exicure, Inc. Reports First Quarter 2019 Financial Results and Reviews Corporate Progress

05/03/2019

Exicure to Present Poster at AAN 2019

04/30/2019

Exicure to Present Poster at ARVO 2019

04/01/2019

Exicure to Present at H.C. Wainwright Global Life Sciences Conference 2019

04/01/2019

Exicure to Present at the AACR Annual Meeting 2019

03/26/2019

Exicure to Present at Spring Investor Summit 2019

03/08/2019

Exicure, Inc. Reports Full Year 2018 Financial Results and Corporate Progress

02/25/2019

Exicure Announces Dosing of First Patient in Phase 1b/2 Immuno-oncology Trial

02/21/2019

Exicure to Present at the 12th Annual European Life Sciences CEO Forum

02/19/2019

Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases

02/18/2019

Exicure to Present at SMi’s RNA Therapeutics 2019 Conference

02/06/2019

Exicure to Present at BIO CEO & Investor Conference 2019

02/05/2019

Exicure Announces US Clinical Sites for Phase 1b/2 Oncology Trial

02/04/2019

Exicure to Present at the Immuno-Oncology 360° Conference

01/03/2019

Exicure to Present at Biotech Showcase 2019 on January 8th at 2:30 pm PT